公开(公告)号：US11079386B2

公开(公告)日：2021-08-03

申请号：US16336846

申请日：2017-10-04

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Yosuke Harada ,  Tatsuki Yokoseki ,  Yusuke Nakamura

IPC: G01N33/574 ,  C07K16/28

Abstract: The present invention relates to monoclonal antibodies against FZD10. Furthermore, the present invention provides methods for diagnosing FZD10-related diseases using such an antibody, methods for detecting a FZD10 protein, methods for determining drug efficacy after treatment with FZD10 inhibitors, and methods of screening for subjects in whom treatment with FZD10 inhibitors is highly effective, and provides diagnostic reagents containing such an antibody.

公开(公告)号：US20200255474A1

公开(公告)日：2020-08-13

申请号：US16631141

申请日：2018-07-18

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa KATAGIRI ,  Tetsuro YOSHIMARU ,  Takashi MIYAMOTO ,  Yasuhide OKAMOTO

IPC: C07K7/08 ,  A61P35/00 ,  A61K47/65

Abstract: The present invention provides peptides having a structure in which portions of a dominant-negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 are replaced by at least two stapling structures. The peptides of the present invention have excellent cell growth inhibiting activity. The cell growth inhibiting activity lasts longer, compared to a single-stapled peptide. Therefore, the peptides of the present invention have a feature suitable for clinical applications in cancer therapy.

公开(公告)号：US10669310B2

公开(公告)日：2020-06-02

申请号：US16070896

申请日：2017-01-16

Applicant: TOKUSHIMA UNIVERSITY ,  ONCOTHERAPY SCIENCE, INC.

Inventor： Toyomasa Katagiri ,  Takashi Miyamoto ,  Rie Hayashi

IPC: A61K38/10 ,  C07K7/04 ,  A61K38/00 ,  C07K7/00 ,  A61P35/00 ,  A61K38/03

Abstract: The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.

公开(公告)号：US20200155596A1

公开(公告)日：2020-05-21

申请号：US16773487

申请日：2020-01-27

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya TSUNODA ,  Ryuji OSAWA ,  Sachiko YAMASHITA ,  Tomohisa WATANABE ,  Tetsuro HIKICHI

IPC: A61K35/14 ,  C12N15/09 ,  C12N5/10 ,  C07K7/08 ,  C07K7/06 ,  C07K16/18 ,  A61K48/00 ,  A61K39/00 ,  A61K35/12

Abstract: The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US10576097B2

公开(公告)日：2020-03-03

申请号：US15500895

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yamashita ,  Tomohisa Watanabe ,  Tetsuro Hikichi

IPC: A61K39/00 ,  A61K31/7088 ,  A61K38/00 ,  A61K48/00 ,  C12N15/09 ,  C07K7/06 ,  C07K7/08 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20190185575A1

公开(公告)日：2019-06-20

申请号：US16328259

申请日：2017-08-25

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： Yosuke HARADA ,  Suyoun CHUNG ,  Yusuke NAKAMURA

IPC: C07K16/30 ,  C12N15/85 ,  G01N33/573 ,  G01N33/574

CPC classification number: C07K16/30 ,  C07K16/18 ,  C12N15/85 ,  C12N2015/8518 ,  G01N33/573 ,  G01N33/57492 ,  G01N2800/364 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention relates to monoclonal antibodies against MELK. Furthermore, the present invention provides methods for diagnosing MELK-associated diseases using the antibodies, methods for detecting the MELK protein, methods for determining the drug efficacy following treatment with a MELK inhibitor, methods of screening for subjects to whom a MELK inhibitor has a high therapeutic effect, and diagnostic reagents containing the antibodies.

公开(公告)号：US10206989B2

公开(公告)日：2019-02-19

申请号：US15411115

申请日：2017-01-20

Applicant: OncoTherapy Science, Inc.

Inventor： Yasuharu Nishimura ,  Yusuke Tomita ,  Ryuji Osawa

IPC: A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C12N5/0783 ,  C07K16/28 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K16/30 ,  C12N5/078

Abstract: Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

公开(公告)号：US10172926B2

公开(公告)日：2019-01-08

申请号：US15385141

申请日：2016-12-20

Applicant: OncoTherapy Science, Inc.

Inventor： Yasuharu Nishimura ,  Yusuke Tomita ,  Ryuji Osawa

IPC: C07K14/00 ,  A61K39/00 ,  A61K38/00 ,  C12N5/0783 ,  C12N9/14 ,  C07K16/28 ,  C07K16/30 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C12N5/078

Abstract: Isolated KIF20A-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce KIF20A-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

公开(公告)号：US20180079791A1

公开(公告)日：2018-03-22

申请号：US15500906

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： TAKUYA TSUNODA ,  RYUJI OSAWA ,  SACHIKO YAMASHITA ,  TOMOHISA WATANABE

IPC: C07K14/47 ,  C07K16/18 ,  G01N33/574 ,  A61K39/00 ,  G01N33/50

Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

公开(公告)号：US20180042954A1

公开(公告)日：2018-02-15

申请号：US15500895

申请日：2015-07-31

Applicant: ONCOTHERAPY SCIENCE, INC.

Inventor： TAKUYA TSUNODA ,  RYUJI OSAWA ,  SACHIKO YAMASHITA ,  TOMOHISA WATANABE ,  TETSURO HIKICHI

IPC: A61K31/7088 ,  C07K7/08 ,  G01N33/50 ,  C12Q1/02 ,  G01N33/15 ,  C07K7/06 ,  C12N15/09

Abstract: The present invention provides URLC10-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.